跳至主要内容
临床试验/EUCTR2012-000812-27-NL
EUCTR2012-000812-27-NL进行中(未招募)1 期

The analgesic efficacy of ?9-THC (Namisol®) in patients with persistent postsurgical abdominal pain: a randomized, double-blinded, placebo-controlled, parallel design’ - Delta-Pain III

Radboud University Nijmegen Medical Centre0 个研究点目标入组 68 人开始时间: 2012年7月23日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
68

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Aged 18 years or older
  • Postsurgical pain
  • Pain duration exceeding 3 months, and average NRS=3
  • Stable doses intake of analgesics for the past 2 months
  • The patient has been informed about the study, understood the information and signed the informed consent form
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 68
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Patient is diagnosed with irritated bowel syndrome (IBS) or chronic pancreatitis
  • Patient has an indication for a pain treatment other then medication
  • Patient took cannabinoids on a regular basisin past 3 years
  • Patient does not feel a pinprick test in the lower extremities
  • Patient has a body mass index (BMI) above 33,0 kg/m2
  • Patient has a significant medical disorder that may interfere with the study or may pose a risk for the patient
  • Patient uses any kind of concomitant medication that may interfere with the study or may pose a risk for the patient
  • Patient does not tolerate oral intake of medication or liquids, or is refrained from oral intake because of medical reasons
  • Patient demonstrates clinical relevant deviations in the electrocardiogram (ECG)
  • Patient has an actual moderate to severe renal impairment
  • Patient has an actual moderate to severe hepatic impairment
  • Patient has a presence or history of major psychiatric illness
  • Patient has experienced an epileptic seizure in the past
  • Patient demonstrates clinically significant laboratory abnormalities
  • Patient demonstrates a positive urine drug screen for THC, cocaine, MDMA, and amphetamines
  • Patient an active hepatitis B, hepatitis C or HIV infection
  • Patient has a history of sensitivity / idiosyncrasy to THC
  • Patient has a known or suspected lactose intolerance
  • Female patient is pregnant or breastfeeding
  • Patient intends to conceive a child during the course of the study
  • Patient participates in another investigational drug study
  • Patient has a clinical significant exacerbation in illness
  • Patient is unwilling or unable to comply with the lifestyle guidelines

研究者

发起方
Radboud University Nijmegen Medical Centre

相似试验